| Id: | acc2173 |
| Group: | 2sens |
| Protein: | PELP1 |
| Gene Symbol: | PELP1 |
| Protein Id: | Q8IZL8 |
| Protein Name: | PELP1_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser1033 |
| Site Sequence: | PTLAPEALPSQGEVEREGESP |
| Disease Category: | Cancer |
| Disease: | Breast Cancer |
| Disease Subtype: | |
| Disease Cellline: | ZR75 |
| Disease Info: | |
| Drug: | camptothecin |
| Drug Info: | "Camptothecin is a naturally occurring alkaloid derived from the Chinese tree Camptotheca acuminata, which functions as a topoisomerase I inhibitor, disrupting DNA replication and exhibiting antitumor activity in various cancers, including colorectal, ovarian, and lung cancers." |
| Effect: | increase |
| Effect Info: | Protein phosphorylation enhances the sensitivity to drug therapy. |
| Note: | |
| Score: | 5.0 |
| Pubmed(PMID): | 24786831 |
| Sentence Index: | 24786831_4-5 |
| Sentence: | "PELP1 is phosphorylated at Serine1033 by various DDR kinases like ataxia-telangiectasia mutated, ataxia telangiectasia and Rad3-related or DNAPKc and this phosphorylation of PELP1 is important for p53 coactivation functions. PELP1-depleted p53 (wild-type) breast cancer cells were less sensitive to various genotoxic agents including etoposide, camptothecin or gamma-radiation." |
Sequence & Structure:
MAAAVLSGPSAGSAAGVPGGTGGLSAVSSGPRLRLLLLESVSGLLQPRTGSAVAPVHPPNRSAPHLPGLMCLLRLHGSVGGAQNLSALGALVSLSNARLSSIKTRFEGLCLLSLLVGESPTELFQQHCVSWLRSIQQVLQTQDPPATMELAVAVLRDLLRYAAQLPALFRDISMNHLPGLLTSLLGLRPECEQSALEGMKACMTYFPRACGSLKGKLASFFLSRVDALSPQLQQLACECYSRLPSLGAGFSQGLKHTESWEQELHSLLASLHTLLGALYEGAETAPVQNEGPGVEMLLSSEDGDAHVLLQLRQRFSGLARCLGLMLSSEFGAPVSVPVQEILDFICRTLSVSSKNISLHGDGPLRLLLLPSIHLEALDLLSALILACGSRLLRFGILIGRLLPQVLNSWSIGRDSLSPGQERPYSTVRTKVYAILELWVQVCGASAGMLQGGASGEALLTHLLSDISPPADALKLRSPRGSPDGSLQTGKPSAPKKLKLDVGEAMAPPSHRKGDSNANSDVCAAALRGLSRTILMCGPLIKEETHRRLHDLVLPLVMGVQQGEVLGSSPYTSSRCRRELYCLLLALLLAPSPRCPPPLACALQAFSLGQREDSLEVSSFCSEALVTCAALTHPRVPPLQPMGPTCPTPAPVPPPEAPSPFRAPPFHPPGPMPSVGSMPSAGPMPSAGPMPSAGPVPSARPGPPTTANHLGLSVPGLVSVPPRLLPGPENHRAGSNEDPILAPSGTPPPTIPPDETFGGRVPRPAFVHYDKEEASDVEISLESDSDDSVVIVPEGLPPLPPPPPSGATPPPIAPTGPPTASPPVPAKEEPEELPAAPGPLPPPPPPPPPVPGPVTLPPPQLVPEGTPGGGGPPALEEDLTVININSSDEEEEEEEEEEEEEEEEEEEEEDFEEEEEDEEEYFEEEEEEEEEFEEEFEEEEGELEEEEEEEDEEEEEELEEVEDLEFGTAGGEVEEGAPPPPTLPPALPPPESPPKVQPEPEPEPGLLLEVEEPGTEEERGADTAPTLAPEALPSQGEVEREGESPAAGPPPQELVEEEPSAPPTLLEEETEDGSDKVQPPPETPAEEEMETETEAEALQEKEQDDTAAMLADFIDCPPDDEKPPPPTEPDS
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| PELP1-Ser1083 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.425 | ||||||||
| COAD | 0.214 | ||||||||
| HGSC | -1.918 | ||||||||
| ccRCC | |||||||||
| GBM | 1.326 | ||||||||
| HNSC | |||||||||
| LUAD | 0.017 | ||||||||
| LUSC | 0.377 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.44 | ||||||||
| PELP1-Ser1093 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -0.614 | ||||||||
| COAD | 0.447 | ||||||||
| HGSC | -2.437 | ||||||||
| ccRCC | |||||||||
| GBM | 0.646 | ||||||||
| HNSC | 0.519 | ||||||||
| LUAD | 0.258 | ||||||||
| LUSC | 0.525 | ||||||||
| non_ccRCC | |||||||||
| PDAC | 0.675 | ||||||||
| UCEC | -0.019 | ||||||||
| PELP1-Ser1109 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -1.064 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | 0.92 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 0.145 | ||||||||
| PELP1-Ser1123 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -0.146 | ||||||||
| HNSC | 0.625 | ||||||||
| LUAD | -0.516 | ||||||||
| LUSC | -0.848 | ||||||||
| non_ccRCC | 0.377 | ||||||||
| PDAC | 1.725 | ||||||||
| UCEC | -1.218 | ||||||||
| PELP1-Ser527 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -0.414 | ||||||||
| COAD | -1.074 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -0.343 | ||||||||
| HNSC | -0.269 | ||||||||
| LUAD | -0.158 | ||||||||
| LUSC | -0.99 | ||||||||
| non_ccRCC | 2.19 | ||||||||
| PDAC | 0.28 | ||||||||
| UCEC | 0.777 | ||||||||
| PELP1-Ser531 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -0.81 | ||||||||
| COAD | -0.691 | ||||||||
| HGSC | 1.726 | ||||||||
| ccRCC | |||||||||
| GBM | -0.525 | ||||||||
| HNSC | -0.36 | ||||||||
| LUAD | -0.371 | ||||||||
| LUSC | -0.911 | ||||||||
| non_ccRCC | 1.866 | ||||||||
| PDAC | -0.078 | ||||||||
| UCEC | 0.154 | ||||||||
| PELP1-Ser535 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -1.092 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 0.57 | ||||||||
| HNSC | -0.617 | ||||||||
| LUAD | -0.283 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 1.422 | ||||||||
| PELP1-Ser708 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 2.671 | ||||||||
| COAD | -0.319 | ||||||||
| HGSC | -0.323 | ||||||||
| ccRCC | |||||||||
| GBM | 0.171 | ||||||||
| HNSC | -0.151 | ||||||||
| LUAD | -0.297 | ||||||||
| LUSC | -0.321 | ||||||||
| non_ccRCC | -0.562 | ||||||||
| PDAC | -1.035 | ||||||||
| UCEC | 0.165 | ||||||||
| PELP1-Ser793 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.755 | ||||||||
| HGSC | -0.788 | ||||||||
| ccRCC | |||||||||
| GBM | 1.803 | ||||||||
| HNSC | 0.443 | ||||||||
| LUAD | -0.594 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.109 | ||||||||
| PELP1-Thr1064 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | -0.707 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | 0.707 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PELP1-Thr1113 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 1.395 | ||||||||
| HNSC | -0.18 | ||||||||
| LUAD | -0.23 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.985 | ||||||||
| PELP1-Thr1119 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 1.087 | ||||||||
| HNSC | 0.181 | ||||||||
| LUAD | |||||||||
| LUSC | -0.144 | ||||||||
| non_ccRCC | 0.426 | ||||||||
| PDAC | 0.316 | ||||||||
| UCEC | -1.866 | ||||||||
| PELP1-Thr1132 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -2.231 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 0.597 | ||||||||
| HNSC | 0.33 | ||||||||
| LUAD | |||||||||
| LUSC | 0.056 | ||||||||
| non_ccRCC | 0.264 | ||||||||
| PDAC | 0.504 | ||||||||
| UCEC | 0.481 | ||||||||
| PELP1-Thr1140 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.142 | ||||||||
| COAD | |||||||||
| HGSC | -2.448 | ||||||||
| ccRCC | |||||||||
| GBM | 0.149 | ||||||||
| HNSC | 0.424 | ||||||||
| LUAD | 0.481 | ||||||||
| LUSC | 0.543 | ||||||||
| non_ccRCC | |||||||||
| PDAC | 0.412 | ||||||||
| UCEC | 0.298 | ||||||||
| PELP1-Thr538 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | 1.142 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | -0.719 | ||||||||
| LUAD | -0.423 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PELP1-Thr697 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 1.289 | ||||||||
| COAD | -0.764 | ||||||||
| HGSC | 0.06 | ||||||||
| ccRCC | |||||||||
| GBM | 1.408 | ||||||||
| HNSC | 0.603 | ||||||||
| LUAD | |||||||||
| LUSC | -0.633 | ||||||||
| non_ccRCC | -1.457 | ||||||||
| PDAC | 0.362 | ||||||||
| UCEC | -0.867 | ||||||||
| PELP1-Thr795 | |
|---|---|
| Cancer | Intensity |
| BRCA | -1.002 |
| COAD | -0.212 |
| HGSC | -2.334 |
| ccRCC | |
| GBM | 0.786 |
| HNSC | 0.895 |
| LUAD | -0.114 |
| LUSC | 0.699 |
| non_ccRCC | 0.55 |
| PDAC | 0.438 |
| UCEC | 0.296 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 1033 | U | Triple-negative breast cancer | Phosphorylation | 25788226 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 7.709 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 7.9399 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 7.5618 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 7.5743 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 8.3848 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 8.5681 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | HeLa | Curcumin | 1 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | HeLa | CUDC101 | 4.261 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | ARH-77 | Rituximab | -3.6573 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | PC-9 | LapatinibAZD4547 | 5.8514 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | K562 | Dasatinib | 6.2549 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | MK2206 | 6.7322 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A549 | Tideglusib | 5.7221 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A549 | PD325901 | 8.0433 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A549 | MK2206 | 7.2373 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A549 | Dasatinib | 6.76 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A549 | Dasatinib | 7.3458 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | SelumetinibMK2206-3to1 | 6.2652 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | SelumetinibMK2206-1to2 | 11.0573 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | Selumetinib | 6.5941 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | Selumetinib | 7.2756 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | MK2206 | 7.5089 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
